


The various serologies identified

- a very high level of anti-SARS-CoV-2 antibodies.
- a significant reactivation of EBV.
- a moderately active Mycoplasma pneumoniae reaction.

In contrast, Chlamydia pneumoniae serology was negative, and RSV serology was within the normal range. There was also a moderate eosinophilia of 8.1%, indicating the allergic disposition.



Method

These results led us to initiate BI(G)MED therapy. What is this therapeutical approach?

The goal of this method is to regulate dysfunctional molecular processes using ultra-low doses of all kinds of active endogenous molecules. Particular emphasis is placed on the use of various types of non-coding RNAs, especially microRNAs. The key feature of these ultra-low-dose preparations is the stirring-dynamization process, according to a model derived from quantum mechanics, which enables energy transfer movements to take place at the level of molecules affected by a dysfunction.

In this patient, the therapeutic approach took several forms:

- First, the deleterious effects of the vaccine doses received in 2021 had to be neutralized using very high dilutions of these vaccine strains prepared according to the principle described above
- Secondly, the T-lymphocyte balance had to be rebalanced by alternating the prescription of molecular complexes regulating both TH1 and TH2 cells, with the aim of impacting both the reactions linked to the microbial agents detected and the allergic disorders described by the patient.
- The third approach was to neutralize the three reactivated pathogens - EBV, SARS-CoV-2 and Mycoplasma pneumoniae - using products specific to each of them.

Below we show you three examples of this kind of therapeutic formulas.

COMPOSITION	DILUTION
TLR1 gene	1,0x10 ⁻¹⁸ mol. L ⁻¹
TLR2 gene	“
TLR4 gene	“
TLR5 gene	“
TLR6 gene	“
TLR9 gene	“
TLR11 gene	“
Bcl-2 gene	1,0x10 ⁻³⁰ mol. L ⁻¹
IL-10	“
let-7i/e	1,0x10 ⁻⁶⁰ mol. L ⁻¹
miR-9	“
miR-21	“
miR-105	“
miR-125b	“
miR-132	“
miR146a	“
miR-155	“
miR-210	“
miR-223	“
CASPASE-12	“



FORMULA - VIRUSREG

COMPOSITION	DILUTION
IL-33/ST2s	1,0x10 ⁻¹⁸ mol. L ⁻¹
miR-126	1,0x10 ⁻⁸ mol. L ⁻¹
miR-155	“
Dicer	“
TLR3	“
RIG-1	“
MDA5	“
CASPASE-8/10	“
Beclin	“
mTOR	“
IFN α/β	“
IFNAR	“
miR-122	1,0x10 ⁻⁶⁰ mol. L ⁻¹
miR-132	“
miR-146a	“
miR-4661	“
NS2 - NS3/4A	“
SOCS1	“
LGP2	“
TRIM27	“

FORMULA – TH2-REG

COMPOSITION	DILUTION
IL-10	1,0x10 ⁻¹⁸ mol. L ⁻¹
DP	“
miR-23b	1,0x10 ⁻⁸ mol. L ⁻¹
miR-155	“
Bcl11b	“
EP2: G _s	“



PTEN	“
MDA5	“
β2-adrenoreceptor : G _s	“
SHIP	“
Runx3	“
miR-21	1,0x10 ⁻⁶⁰ mol. L ⁻¹
TSLP	“
STAT6	“
GATA-3	“
Jagged 1,2	“
IRF4	“
TRAF6	“
SCF/ c-Kit	“
LAT2	“
Syk	“



Results

After five months of treatment, the patient described a clear improvement in terms of almost complete recovery of taste and smell, as well as a marked regression of all allergic-type symptoms. Biologically, in addition to the normalization of eosinophilic PNs, there was an increase of a small percentage in almost all lymphocyte populations, as well as a return to normal of plasma albumin; the normalization of this parameter was particularly important giving its importance as a marker of long COVID.

Mycoplasma pneumoniae serology has hardly changed, while EBV serology has shown a significant decrease in anti-VCA IgG antibodies. Regarding the SARS-CoV-2 one, it is unfortunately too inaccurate to highlight small-scale changes.



Conclusion

The purpose of this brief description of a clinical case of long COVID is to highlight

- that polymicrobial interactions are involved in the pathogenesis of this syndrome,
- that the improvement of some symptoms, such as ageusia and anosmia, could be accelerated by the implementation of a therapy called BI(G)MED, that is based on the use of ultra-low doses of regulatory endogenous molecules,
- that biological normalization, particularly that linked to viral reactivation, takes longer to be achieved.